Merrimack Pharmaceuticals Inc. Initiates Phase 1 Clinical Study of MM-141 in Patients With Advanced Solid Tumors

CAMBRIDGE, Mass., Dec. 12, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 clinical study of a novel compound for the treatment of advanced solid tumors. MM-141 is a fully human tetravalent antibody designed to target signaling of the P13K/AKT/mTOR pathway driven through IGF-1R and ErbB3 (HER3). It is Merrimack's sixth oncology candidate to enter clinical development.